About: Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study
Creator	Chan, Harvard Hernán, Miguel María, Ana Aguirre, Rumbao Baleares, Oviedo Belén, Ana Blanco, Faustino De Salud, Dirección De Sanidad, Ministerio Fernandez Martinez, Maria Gascón, Calvo Gerencia, Dirección Guadalquivir, Córdoba Gutiérrez, Rodrigo Health, Andalucía Health, Aragón Jiménez, Pérez Manuel, José Martín, Mariano Muñoz-Montalvo, Juan Padrones Fernández, Susana Paniagua, José Rodríguez-Cabrera, Francisco Sanitario, Distrito Sevilla, Sanitario
source	Elsevier; Medline; PMC
abstract	BACKGROUND: Spain is one of the European countries most affected by the COVID-19 pandemic. Serological surveys are a valuable tool to assess the extent of the epidemic, given the existence of asymptomatic cases and little access to diagnostic tests. This nationwide population-based study aims to estimate the seroprevalence of SARS-CoV-2 infection in Spain at national and regional level. METHODS: 35 883 households were selected from municipal rolls using two-stage random sampling stratified by province and municipality size, with all residents invited to participate. From April 27 to May 11, 2020, 61 075 participants (75·1% of all contacted individuals within selected households) answered a questionnaire on history of symptoms compatible with COVID-19 and risk factors, received a point-of-care antibody test, and, if agreed, donated a blood sample for additional testing with a chemiluminescent microparticle immunoassay. Prevalences of IgG antibodies were adjusted using sampling weights and post-stratification to allow for differences in non-response rates based on age group, sex, and census-tract income. Using results for both tests, we calculated a seroprevalence range maximising either specificity (positive for both tests) or sensitivity (positive for either test). FINDINGS: Seroprevalence was 5·0% (95% CI 4·7–5·4) by the point-of-care test and 4·6% (4·3–5·0) by immunoassay, with a specificity–sensitivity range of 3·7% (3·3–4·0; both tests positive) to 6·2% (5·8–6·6; either test positive), with no differences by sex and lower seroprevalence in children younger than 10 years (<3·1% by the point-of-care test). There was substantial geographical variability, with higher prevalence around Madrid (>10%) and lower in coastal areas (<3%). Seroprevalence among 195 participants with positive PCR more than 14 days before the study visit ranged from 87·6% (81·1–92·1; both tests positive) to 91·8% (86·3–95·3; either test positive). In 7273 individuals with anosmia or at least three symptoms, seroprevalence ranged from 15·3% (13·8–16·8) to 19·3% (17·7–21·0). Around a third of seropositive participants were asymptomatic, ranging from 21·9% (19·1–24·9) to 35·8% (33·1–38·5). Only 19·5% (16·3–23·2) of symptomatic participants who were seropositive by both the point-of-care test and immunoassay reported a previous PCR test. INTERPRETATION: The majority of the Spanish population is seronegative to SARS-CoV-2 infection, even in hotspot areas. Most PCR-confirmed cases have detectable antibodies, but a substantial proportion of people with symptoms compatible with COVID-19 did not have a PCR test and at least a third of infections determined by serology were asymptomatic. These results emphasise the need for maintaining public health measures to avoid a new epidemic wave. FUNDING: Spanish Ministry of Health, Institute of Health Carlos III, and Spanish National Health System.
has issue date	2020-07-06(xsd:dateTime)
bibo:doi	10.1016/s0140-6736(20)31483-5
bibo:pmid	32645347
has license	no-cc
sha1sum (hex)	93049c1728ed7c34cfdaf4a7f3ea0e3ed49dacf2
schema:url	https://doi.org/10.1016/s0140-6736%2820%2931483-5
resource representing a document's title	Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study
has PubMed Central identifier	PMC7336131
has PubMed identifier	32645347
schema:publication	Lancet
resource representing a document's body	covid:93049c1728ed7c34cfdaf4a7f3ea0e3ed49dacf2#body_text
is schema:about of	named entity 'Health' named entity 'census tract' named entity 'sampling units' named entity '5.6' named entity 'Spain' named entity '15,000' named entity '3.8' named entity 'percentiles' named entity 'variance' named entity 'census tract' named entity 'SARS-CoV-2' named entity 'probability' named entity 'population density' named entity '90,000' named entity 'autonomous communities' named entity 'seroprevalence' named entity '5.4' named entity 'autonomous communities of Spain' named entity '5.7' named entity '2.6' named entity 'seroprevalence' named entity '3.5' named entity 'sampling units' named entity 'sampling' named entity '5.5' named entity '3.8' named entity 'effective sample size' named entity '7.5' named entity 'design effect' named entity 'sample size' named entity 'confidence level' named entity 'census tract' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2 virus' named entity 'dispersion' named entity '2.2' named entity '8.1' named entity 'effective sample size' named entity '5.2' named entity '3.8' named entity 'sampling units' named entity 'Spanish National Institute of Statistics' named entity 'autonomous communities' named entity 'sampling' named entity '8.3' named entity 'census tract' named entity 'confidence level' named entity '8.1' named entity 'SARS-CoV-2 virus' named entity '90,000' named entity 'variance' named entity '5.4' named entity '4.7' named entity 'sample size' named entity 'seroprevalence' named entity 'randomly selected' named entity '3.5'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software